

SCIENCE. SYNERGY. SUCCESS!



Business of
Biotech 2016
Moffitt Cancer Center



AGENDA

7:45 – 8:45am

BREAKFAST AND NETWORKING

- ATRIUM
-

8:45 – 10:30am

WELCOME AND KEYNOTE ADDRESS

- **Sam Donaldson**, former ABC News correspondent and member of the Moffitt Board of Advisors conducts a conversation with **Dr. Arie Beldegrun**, founder and CEO of Kite Pharma
 - AUDITORIUM
-

11:00am – 12:00pm

BREAKOUT SESSIONS

- *Immuno-Oncology: An Expanding Frontier*
Moderator: Dr. James Mulé, Moffitt Cancer Center
 - FERMAN CONFERENCE ROOM

 - *Be Smart In Financing Your Innovation – All Dollars Are Not The Same*
Moderator: Greg Yadley, Shumaker, Loop & Kendrick, LLP
 - SRB COUCH AUDITORIUM
-

12:00-1:30pm

LUNCH AND NETWORKING

- ATRIUM
-

12:45 – 1:15pm

TOURS

- Cutting Edge/High Tech Research Facilities
 - Hospital
-

1:30 – 3:00pm

BREAKOUT SESSIONS

- *Emerging Trends In Academic & Industry Collaborations*
Moderator: Dr. Bill Dalton, M2Gen
 - *Announce 2017 Date and Keynote*
○ FERMAN CONFERENCE ROOM

 - *Investor Forum*
Moderator: Dr. Haskell Adler, Moffitt Cancer Center
 - *Announce 2017 Date and Keynote*
○ AUDITORIUM
-

OPEN ALL DAY

CHAT. CHARGE. COFFEE!

Network, charge your device and refuel
MURPHEY CONFERENCE ROOM

KEYNOTE INTERVIEW

Arie Beldegrun, M.D., FACS

Kite Pharma

President, Founder and CEO

Arie Beldegrun, M.D., FACS, is the President, Chief Executive Officer, and Founder of Kite Pharma. He also serves as Chairman of the company. He has had a distinguished tenure in the life sciences, having been closely involved with the founding and advancement of a number of successful biopharmaceutical companies. Prior to founding Kite, Dr. Beldegrun was the founding Vice-Chairman of the board of directors and Chairman of the scientific advisory board of Cougar Biotechnology, acquired by Johnson & Johnson in 2009. Previously, Dr. Beldegrun founded and served as Chairman of the board of directors of Agensys, acquired by Astellas Pharma Inc. He currently serves as Chairman of Arno Therapeutics, Two River Group, and TheraCoat Ltd., and as a board member of Teva Pharmaceutical Industries Ltd. In addition, Dr. Beldegrun is a Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, he was at the National Cancer Institute/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. Dr. Beldegrun completed his M.D. at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in Urologic Surgery at Harvard Medical School. He is certified by the American Board of Urology and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons (AAGUS).



Sam Donaldson

Former ABC News Correspondent

Chair Emeritus, Moffitt Board of Advisors

Sam Donaldson is a native of New Mexico, having been raised on a farm in Dona Ana County. He is a high school graduate of New Mexico Military Institute and received a B.A. from Texas Western College (now UTEP). He served two and a half years on active duty in the U. S. Army and achieved the rank of Captain in the USAR. Donaldson was a news reporter based in Washington from February 1961 to October 2013, and he was employed by ABC News from 1967 to 2013. He covered every presidential election during that time, beginning in 1964 with the campaign of Barry Goldwater. Donaldson covered the war in Vietnam and the First Gulf War, he was ABC's Watergate Correspondent, was twice Chief White House Correspondent covering presidents Carter, Reagan, and Clinton, co-anchored the ABC magazine program Prime Time Live with Diane Sawyer, co-anchored the Sunday program This Week with Sam Donaldson and Cokie Roberts, and was the founding anchor of Politics Live, the first regularly scheduled Monday through Friday news program in the United States on the Internet. Donaldson has ranching interests in New Mexico and now lives in Albuquerque with his wife Sandra.



IMMUNO-ONCOLOGY: AN EXPANDING FRONTIER

11:00 a.m. - 12:00 p.m. - Ferman Conference Room

MODERATOR



James Mulé, Ph.D.
Moffitt Cancer Center
Associate Center Director for
Translational Science

Dr. Mulé is the Associate Center Director for Translational Science, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and Director of Cell-Based Therapies at Moffitt Cancer Center. Dr. Mulé, who recently was designated a "Master of Immunology" by the American Association for Cancer Research, serves on Advisory Boards of numerous biotechnology and pharma companies (e.g., OncoPep, Lion Biotech, Oxis Biotech, Vault Nano, and Celgene, among others). Dr. Mulé remains a long-standing special government employee to the FDA (CDER and CBER) and the NCI. He was Chair of the Cellular, Tissue, and Gene Therapy Advisory Committee of CBER, FDA. Dr. Mulé has published nearly 200 articles in the areas of cancer vaccines and cancer immunotherapy.

PANELISTS



Doug Calder
President, Vycellix, Inc.
Director of Development &
Strategic Planning, NSU Cell
Therapy Institute

Doug Calder currently serves as President of Vycellix, Inc., a cancer immunotherapy start-up focused on the development of novel natural killer cell-based technologies. Mr. Calder also serves as Director of Development & Strategic Planning at Nova Southeastern University's NSU Cell Therapy Institute in Ft. Lauderdale, Florida. The NSU Cell Therapy Institute is accelerating the advancement of next-generation approaches to precision medicine such as targeted immunotherapy and regenerative medicine. Mr. Calder has held various senior executive roles for Florida-based biotechnology companies and research institutes including Viragen, Accentia Biopharmaceuticals, Biovest, and the Vaccine & Gene Therapy Institute of Florida. Mr. Calder also serves on the Board of Directors of BioFlorida.



Mary Christian, Pharm.D.
Bristol-Myers Squibb
Head of Oncology Academic
Research

Mary Christian is the Head of the Oncology Academic Research (OAR) group at Bristol-Myers Squibb. Partnering with the clinical, scientific, and administrative leadership of cancer institutions, this group is charged with building and efficiently executing strategically aligned plans that respond to the needs of key institutions while balancing Bristol-Myers Squibb's pipeline, medical, and data needs. Previously, Mary was the Head of Mature Products for the Research & Development organization. Prior to joining BMS, Mary worked in Regulatory Affairs at Johnson & Johnson Pharmaceutical Research & Development, where she led regulatory teams across a number of therapeutic areas, including neuroscience, women's health, and internal medicine. Mary received her undergraduate degree at Rutgers University and a doctorate in Clinical Pharmacy from the University of Florida. She also holds an M.B.A. in Pharmaceutical Business from the University of the Sciences in Philadelphia.



Elma Hawkins, Ph.D.
Lion Biotechnologies
President and CEO

Dr. Hawkins' 30-year career encompasses pioneering efforts in biotechnology drug development and executive roles in corporate development, strategy, fundraising, and general management. Her therapeutic expertise is in oncology, infectious diseases, and wound healing. She started her career at Warner-Lambert/Parke-Davis in Clinical Research. Later, she joined the Center for the Study of Drug Development at Tufts Medical School. Following that, she held various positions at BioSurface Technology and Genzyme and was later Vice Chairman of Antigenics. She was subsequently President and CEO of Advanced Viral Research. Dr. Hawkins is currently President and Chief Executive Officer of Lion Biotechnologies. She is also Chairman of EpiBone and the founder and President of Viridian Pharmaceuticals. Dr. Hawkins has a B.Sc. in Mathematics and Chemistry, B.Sc. (Hons) in Chemistry, M.Sc. in Organic Chemistry, a Ph.D. in Organic Chemistry and an M.B.A. with specialization in entrepreneurship.



Rahul Jasuja, Ph.D.
NOBLE Life Science Partners
Managing Director, Biotechnology
Research

Dr. Jasuja is currently the managing director of biotechnology research at NOBLE Life Science Partners (NLSP). He is also a Board Observer at Pelican Therapeutics, developing a novel T-cell co-stimulator for immuno-oncology. Prior to NLSP, he was the Vice President of Corporate Development at Idera Pharmaceuticals, focused on developing Toll-like receptor based immune-modulators. Previously Dr. Jasuja held progressively senior positions in the biotechnology capital markets at Techvest, Rodman & Renshaw, and MDB Capital Group. He obtained his B.Sc. in Microbiology & Biochemistry from the University of Bombay and his M.S. in Microbiology from the University of Montana, Missoula. Dr. Jasuja received his Ph.D. in Immunology from Tufts University School of Medicine.



Frederick Locke, M.D.
Moffitt Cancer Center
Chair, Cellular Therapy Advisor
Committee

Dr. Locke is a physician and translational investigator specializing in the treatment of lymphoma and multiple myeloma in the Department of Blood and Marrow Transplantation at Moffitt. He is focused on developing strategies to promote T-cell responses against tumor-associated antigens for patients with these diseases and is the principal investigator for multiple cellular immunotherapy trials. He is a lead investigator for two national multi-center phase I/II studies treating aggressive lymphoma patients with KTE-C19 Chimeric Antigen Receptor T-cells. Dr. Locke is the Chair of the Moffitt Cellular Therapy Advisory Committee and the Chair of the Moffitt Immunotherapy Working Group. In addition, he is the Service Chief of the Moffitt Immune and Cellular Therapy (ICE-T) service, which was created to provide specialized clinical care for patients undergoing cellular immunotherapy treatments.

SAVE THE DATE

Business of
Biotech 2017
Moffitt Cancer Center

FEBRUARY 24, 2017

BE SMART IN FINANCING YOUR INNOVATION - ALL DO

11:00 a.m. - 12:00 p.m. - Couch Auditorium

MODERATOR



Greg Yadley
Partner
Shumaker, Loop & Kendrick, LLP

Greg Yadley has extensive experience representing business entities of all sizes, including closely-held and family businesses and large and small public companies. He regularly represents these clients in financing transactions, mergers and acquisitions, contract negotiations and disputes, strategic planning, legal compliance, and general corporate matters. Greg is an adjunct professor at the University of Florida's Levin College of Law, a frequent lecturer, and a member of the U.S. Securities and Exchange Commission's Advisory Committee on Small and Emerging Businesses. He is a Co-Editor of The Florida Bar Florida Corporate Practice Manual and Co-Director of the annual Federal Securities Institute. Greg serves as the Chairman of the American Bar Association's Middle Market and Small Business Committee.

PANELISTS



Tavera Andrews, CPA
Applied Genetic Technologies
Corporation
Controller and Director of Finance

Tavera Andrews is the Controller and Director of Finance of Applied Genetic Technologies Corporation (AGTC). Since joining AGTC in 2010, Tavera has supported a collaboration agreement with a major biotech company, which garnered a \$124 million upfront payment, assisted in completing public offerings totaling \$92 million, and aided in securing investments of over \$44 million from nationally recognized venture capitalists and granting agencies. Andrews' career has included six years in public accounting, where her emphasis had been on financial audits of entities with significant grant expenditures. She received her Bachelor of Science in Accounting from the University of Florida and received her M.B.A. in Accounting from Saint Leo University.



Michael Cerio
Signal Genetics
Chief Commercial Officer

Mr. Cerio serves as the Chief Commercial Officer of Signal Genetics. He joined the company as the Senior Vice President of Commercial Strategy and Business Development in August 2014. Prior to joining Signal Genetics, Mr. Cerio served as an independent consultant with the life science venture capital firm MPM Capital. From June 2012 to April 2013, Mr. Cerio served as Consulting Chief Executive Officer for Modulation Therapeutics, a Moffitt Cancer Center startup. From April 2012 to April 2013, Mr. Cerio was the President and Chief Executive Officer of Oncolome Diagnostics. From 2005 through 2011, Mr. Cerio led the licensing, early commercial strategy, and merger and acquisition teams at Genzyme Genetics. From 1999 through 2005, Mr. Cerio held business development and licensing roles at BG Medicine and Genaissance Pharmaceuticals. Mr. Cerio holds a B.S. in biology from Syracuse University, an M.S. in microbiology from the University of Connecticut and an M.B.A. from Columbia University.



Douglas Hamilton
MetaStat, Inc.
President and Chief Executive
Officer

Mr. Hamilton is the President, CEO, and CFO of MetaStat. Previously, he served as the CFO for SEA Medical Systems. In 2007, Mr. Hamilton founded and now serves as Partner at New Biology Ventures, a life-sciences incubator accelerator and consulting firm. From 1999 to 2006, Mr. Hamilton served as CFO and COO for Javelin Pharmaceuticals. While at Javelin, Mr. Hamilton helped build a late stage product pipeline, took the company public, and raised over \$82 million in financing. Prior to Javelin, Mr. Hamilton was the CFO and Director of Business Development for PolaRx Biopharmaceuticals, Inc. At PolaRx, he helped develop the orphan drug Trisenox® and co-led the \$45.2 million merger with Cell Therapeutics. Mr. Hamilton earned his honors Bachelor of Science degree from the University of Toronto and his M.B.A. from the Ivey Business School at Western University.

LLARS ARE NOT THE SAME



Derek Maetzold
Castle Biosciences
Founder, President, and Chief
Executive Officer

A leader in the biopharmaceutical industry for the past 25 years, Derek Maetzold founded Castle Biosciences in 2007 and has successfully overseen the discovery, development, and commercialization of five diagnostic and prognostic tests in cancers, with more in the pipeline. Derek founded the company after a career of successive leadership roles at Encysive Pharmaceuticals, Schering Corporation (now Merck), Integrated Communications, Amylin Pharmaceuticals (now AstraZeneca), and Sandoz (now Novartis). Previously, he served as Officer and Vice President of Marketing and Sales at Encysive Pharmaceuticals. He attended George Mason University, where he received a B.S. in Biology. He received his M.B.A. from the University of California-Riverside.

TEN YEARS OF MOFFITT INNOVATION

473

INTELLECTUAL
PROPERTY
DISCLOSURES

366

ORIGINAL
U.S. PATENT
APPLICATIONS

58

U.S. PATENTS
ISSUED

153

LICENSES

8

ACTIVE
STARTUPS

\$30
MILLION

2015 - 2016
GLOBAL
FUNDING

EMERGING TRENDS IN ACADEMIC & INDUSTRY COLLABORATIONS

1:30 p.m. - 3:00 p.m. - Ferman Conference Room

MODERATOR



Bill Dalton, Ph.D., M.D.
M2Gen
Founder and CEO

Dr. Bill Dalton serves as Founder and CEO of M2Gen, a national biotechnology subsidiary of Moffitt Cancer Center. Before taking this role, he was the President and CEO of Moffitt Cancer Center from 2002 to 2012. He currently serves as the President of the Association of American Cancer Institutes, chairs the Science Policy & Legislative Affairs Committee of the American Association for Cancer Research, and serves on the Institute of Medicine's National Cancer Policy Forum and various NCI, cancer center, and research foundation scientific advisory boards across the U.S. In addition, Dr. Dalton serves at the state level as a member of the Florida Council of 100, an advisory role to the Governor, the Chief Justice, the Legislature, as well as private organizations, to promote the economic growth of Florida and improve the economic well-being and quality of life of the citizens of Florida.

PANELISTS



Gertjan Bartlema
Celgene Corporation
Vice President of Corporate Franchise Operations

Gertjan Bartlema is the Vice President of Corporate Franchise Operations at Celgene Corporation. Prior to this role, Gertjan held the positions of General Manager Middle East, Africa & Greece and Executive Director of Marketing & Sales Excellence for Celgene Europe, Middle East and Africa (EMEA). He previously was a member of Celgene's Business Development team that acquired Gloucester Pharmaceuticals Inc. and Abraxis BioScience Inc. Mr. Bartlema started with Celgene in May 2006 in Business Planning EMEA based in Neuchatel, Switzerland. Prior to joining Celgene, he worked at Amgen, where he started his career in biotech in 1997 at their European headquarters. He joined their Corporate Financial Planning & Analysis group in 1999. Mr. Bartlema holds a Masters in Economics from Maastricht University, The Netherlands.



Stephen Eck, M.D., Ph.D.
Astellas Pharma
Vice President, Global Head of Oncology Sciences

Dr. Eck is the Vice President of Oncology Medical Sciences at Astellas, where he is responsible for the design and conduct of oncology studies in all phases of clinical development. Dr. Eck previously served as Vice President of Translational Medicine & Pharmacogenomics at Eli Lilly, where he was responsible for the clinical pharmacology components of drug development. Dr. Eck is a Hematologist/Oncologist with broad drug development experience in Oncology and Neuroscience and is a Fellow of the American Association for the Advancement of Science. He serves on the Board of Directors of Luminex Corporation, on the Scientific Advisory Board of the ACGT Foundation, on the Board of Trustees of the Keck Graduate School, on the Board of Directors of the Central Pennsylvania Clinic, and on the Board of Directors of the Personalized Medicine Coalition.



Eric Rubin, M.D.
Merck Research Laboratories
Vice President and Therapeutic Area Head, Oncology Early Development

Dr. Rubin has focused on cancer drug development for over 20 years, initially as a faculty member at the Dana-Farber Cancer Institute, and then as a senior leader of the Cancer Institute of New Jersey. In 2008, Dr. Rubin was recruited to Merck as the Vice President of Oncology Clinical Research. He led the development of the first anti-PD-1 therapy approved in the U.S. and in the identification of the significant activity of this antibody across several additional cancer types. In his current role, he oversees oncology early development and translational research activities at Merck. He has served as a member of National Cancer Institute and American Cancer Society study sections as well as on program committees for the American Association of Cancer Research and the American Society of Clinical Oncology. Dr. Rubin obtained his medical degree from the University of South Florida and completed residency at Yale-New Haven Hospital.

TEN YEARS OF BUSINESS OF BIOTECH CONFERENCE KEYNOTE SPEAKERS

2016 - Arie Beldegrun
President & CEO
Kite Pharma



2015 Henri Termeer
Former CEO, Genzyme

Steven Burrill
CEO, Burrill & Company

2014

2013 Bob Ingram
General Partner
Hatteras Venture Partners

Risa Stack
Partner
Kleiner Perkins Caufield

2012

2011 Robert Tepper
Partner, Third Rock

Garry Nolan
Founder, Nodality, Inc.
Founder, Rigel, Inc.

2010

2009 David Hale
Hale BioPharma Ventures
Former CEO, Hybritech

Rusty Williams
Founder
Prime Therapeutics

2007

2006 Steven Gillis
ARCH Venture Partners
Founder, Corixa Corp.

INVESTOR FORUM

1:30 p.m. - 3:00 p.m. - Couch Auditorium

MODERATOR



Haskell Adler, Ph.D.
Moffitt Cancer Center
Office of Technology Management and Commercialization

Haskell Adler is currently the senior licensing manager at Moffitt Cancer Center, where he helps researchers and clinicians patent and license their inventions and form startups around Moffitt technologies. Haskell became a registered patent agent with the U.S. Patent and Trademark Office in 2016. Haskell was previously a Science Advisor in the Intellectual Property Practice of the law firm Needle & Rosenberg, which was acquired by Ballard Spahr. He previously worked as a Principal at Georgia Venture Partners, an early-stage biomedical Venture Capital Fund. Haskell was the Interim CEO of Axona Inc, a Georgia Venture Partners portfolio company. Prior to Georgia Venture Partners, Haskell was an analyst at both Kilkenny Capital Management and S Squared Technology Corporation. Haskell holds an M.B.A. in finance from the Yale School of Management and a Ph.D. in chemistry from the University of California at San Diego and the Salk Institute.

STARTUPS

AVATAR DSS



AvatarDSS brings a high quality mDSS solution to the marketplace that, rather than trying to statistically fit a patient to a generic treatment plan, uses advanced mathematical modeling to match a specific and customized plan to an individual patient. The patented technology for the platform is licensed from Moffitt Cancer Center, while the individual disease models are developed and clinically validated by research teams and independent review boards. The integrated mechanisms, and action based algorithms in the models, enable the system to determine the best treatment even for the most complex cases where historical data is of limited use. The AvatarDSS platform is being designed to be integrated with any number of Electronic Health Records, or hospital management systems, or be delivered as a standalone solution. We enable physicians to quickly select the most efficient treatment plan for a particular patient and provide health plans with the assurance that every option has been considered. Even though the initial disease models are specific to cancer, the platform is being designed to support any disease planning that requires complex decision making.



CVERGENX, INC.

Cvergenx, Inc. is an early-stage genomic informatics company that provides decision support to radiation oncologists to enable precision genomic radiation therapy (pGRTM). Developed in collaboration with Moffitt Cancer Center, this critical advance in personalized medicine represents the first approach to genomic radiation therapy for the treatment of cancer. Utilizing the proprietary Radiosensitivity Index (RSI) and Genomic Adjusted Radiation Dose (GARD), Cvergenx projects that the pGRTM platform has the potential to expand the current worldwide radiation treatment planning, software and services market by more than 50%, approximately \$1 billion.



GLG PHARMA, LLC.

GLG Pharma, LLC, is developing targeted therapies (STAT3 inhibitors) licensed from Moffitt Cancer Center and the Dana Farber Cancer Institute (Boston, MA). The company is currently focused on cancer and autosomal dominant polycystic kidney disease (ADPKD). The company has received more than \$4.7 million in support from the US NCI PREVENT breast cancer program, as well as NCBP Poland (\$2.7 million; triple negative breast cancer clinical trial) and is seeking \$10 million to expand clinical trials.



INTERPARES BIOMEDICINE, INC.

Interpares Biomedicine (IPB) is an early-stage medical therapeutics company focused on providing personalized medicine solutions to inform cancer immunotherapy decisions. IPB provides guidance on immuno-oncology selection for patients with metastatic solid tumors without the need for tissue biopsy. IPB will provide a CLIA/CAP reference laboratory, with initial tests being blood-based proprietary predictors of benefit from CTLA-4 inhibitor and PD-1 inhibitors. The pipeline includes markers of severe or life-threatening immunotherapy toxicity, predictors of altered efficacy, and guidance for single agent versus combination immunotherapy. IPB is well positioned to provide essential information to drug developers, clinical oncologists, and healthcare payers as they optimize the application of the many new immunotherapy options for cancer treatment.

PANELISTS



Robert L. Crutchfield
General Partner
Harbert Management Company

Mr. Crutchfield joined Harbert Management Corporation in September 2008 and serves on the boards of CareSync, IngagePatient and WellCentive. He also serves as the Board Observer for Wisertogether, MaxCyte, and Social SafeGuard. In addition to his responsibilities at Harbert, he is a member of the Board of Directors for the Nashville Health Care Council, Southeastern Medical Device Association, the Southern Capital Forum, the Florida Venture Forum, the Innovation Depot, and the True Vine Foundation. He serves on the Board of Advisors for the University of Georgia's Innovation Gateway Incubator. He is also a member of the Investor Advisory Board for the Florida Institute for the Commercialization of Public Research, serves as the Co-Chairman of the Innovation Depot's Funding Committee, and is a part of their Velocity Program Committee. He is involved in the Venture Fellows program at the University of Alabama in Tuscaloosa and is a Visiting Executive in Residence at Auburn University.



Matt Rice
Partner
Ballast Point Ventures

Matt Rice is a Partner at Ballast Point Ventures. Prior to joining Ballast Point Ventures in 2004, Matt Rice worked in the Strategic Alliances group at the Novartis Institutes for BioMedical Research. He also served as an Analyst in the Health Care Investment Banking Group at Raymond James, where he focused primarily on the specialty pharmaceutical, drug distribution, and contract research organization sectors. He graduated from the University of Virginia with a bachelor's degree in Commerce and from the Harvard Graduate School of Business Administration with an M.B.A. Matt leads BPV's health care practice and currently serves on the board of directors at Iconix, MolecularMD, TissueTech, and Y-Prime and previously represented BPV at Innocutis. He also serves on the Board of Directors of the Florida Venture Forum.



David R. Scholl, Ph.D.
Partner
Athenian Venture Partners

Dave Scholl served as President and CEO of Diagnostic Hybrids, Inc. from 1997-2010 and was elected Chairman in 2006. A clinical virology diagnostics company, DHI grew to \$50 million in revenues and nearly 250 employees from an Ohio University-based start-up. Dave joined Athenian Venture Partners as a scientific consultant in 1997 and became a part-time partner in the firm's healthcare practice in 2000. Dave has served on numerous governing boards, including BioOhio, the Ohio Third Frontier Commission, the Ohio University Board of Trustees, and The Foundation for Ichthyosis and Related Skin Types, Inc. (FIRST), a non-profit focused on rare skin diseases based in Philadelphia. Dave was Central Ohio's Ernst and Young Entrepreneur of the Year in 2003. He was a Post-Doctoral Research Fellow at the Roche Institute for Molecular Biology after receiving his Ph.D. from Ohio University and his B.S. from Indiana University.



Randy Scott
Partner
Healthquest Capital

Randy Scott is a Partner with HealthQuest Capital. HealthQuest Capital manages a \$110 million fund, investing capital into revenue-stage innovative companies in the healthcare field. For HealthQuest's portfolio, he serves on the Board of Vestagen and is a Board Observer on Trice Medical, First Aid Shot Therapy, and Virmedica. Prior to moving into venture capital, Randy was a successful medtech entrepreneur. He founded NovaMin Technology Inc., grew the company, and remained as CEO through its successful sale to GlaxoSmithKline. Prior to NovaMin, Randy served as President of USBiomaterials Corp. He began his career at Procter & Gamble and was also part of the early management team at LensCrafters as it transitioned from start-up to explosive growth. He is a graduate of Georgia Tech and holds a B.S. in management science and resides in Gainesville, FL.

THANKS TO OUR SPONSORS

HOST PARTNER



PLATINUM



GOLD



BAG SPONSOR



HILL WARD
HENDERSON
ATTORNEYS AT LAW

EXHIBIT SPONSOR



PROMOTIONAL MATERIAL SPONSOR

